Impact of Serogroup a Meningococcal Conjugate Vaccine for Africa

Human Vaccines and Immunotherapeutics - United States
doi 10.1080/21645515.2017.1412022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Adoption of Serogroup B Meningococcal Vaccine Recommendations

Pediatrics
Child HealthPediatricsPerinatology
2018English

Development of a Glycoconjugate Vaccine to Prevent Meningitis in Africa Caused by Meningococcal Serogroup X

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2013English

Potential Benefits of Using a Multicomponent Vaccine for Prevention of Serogroup B Meningococcal Disease

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2019English

Impaired Antibody Response to Conjugated Meningococcal Serogroup C Vaccine in Asplenic Patients

European Journal of Clinical Microbiology and Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2010English

Modelling Cost Effectiveness of Meningococcal Serogroup C Conjugate Vaccination Campaign in England and Wales

BMJ
2002English

Maintenance of Immune Response Throughout Childhood Following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2012English

Meningococcal Serogroup B Vaccine Immunogenicity in High-Risk Groups: What Are the Implications?

Pediatrics
Child HealthPediatricsPerinatology
2018English

A Licensed Combined Haemophilus Influenzae Type B-Serogroups C and Y Meningococcal Conjugate Vaccine

Infectious Diseases and Therapy
Infectious DiseasesMicrobiology
2013English

Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for Use by Provinces and Territories

Canada Communicable Disease Report
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy